Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DYN 101

Next Previous
Drug Profile

DYN 101

Alternative Names: DYN-101; IONIS-DNM2-2.5Rx

Latest Information Update: 06 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Flamingo Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Dynamin II protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital structural myopathies

Most Recent Events

  • 02 Mar 2023 Dynacure has merged with Flamingo Therapeutics to form Flamingo Therapeutics
  • 07 Jul 2022 Dynacure withdrew phase I/II DyNaMic trial in Congenital structural myopathies (In children, In adolescents) in France and Germany (IV) (EudraCT2020-004608-32) (NCT04743557)
  • 22 Jun 2022 Dynacure terminated the phase I/II Unite-CNM trial in Congenital structural myopathies (In adolescents, In adults, In the elderly) in Belgium, Denmark, France, Germany, Netherlands and United Kingdom (IV) due to tolerability results (NCT04033159) (EudraCT2018-004089-33)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top